EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination

Ilya Kister iD, Ryan Curtin, Amanda L Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E Bacon iD, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva und 8 weitere

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Ilya Kister und 19 weiteren Autor:innen. Beteiligte Einrichtung: NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Monoclonal, Humanized, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

(1) To plot the trajectory of humoral and cellular immune responses to the primary (two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple sclerosis (MS) patients up to 2 years post‐vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID‐19 infections on SARS CoV‐2‐specific immunity.

Methods

Sixty ocrelizumab‐treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers. Samples were collected pre‐vaccination, and then 4, 12, 24, and 48 weeks post‐primary series, and 4, 12, 24, and 48 weeks post‐booster. Binding anti‐Spike antibody responses were assessed with multiplex bead‐based immunoassay (MBI) and electrochemiluminescence (Elecsys®, Roche Diagnostics), and neutralizing antibody responses with live‐virus immunofluorescence‐based microneutralization assay. Spike‐specific cellular responses were assessed with IFNγ/IL‐2 ELISpot (Invitrogen) and, in a subset, by sequencing complementarity determining regions (CDR)‐3 within T‐cell receptors (Adaptive Biotechnologies). A linear mixed‐effect model was used to compare antibody and cytokine levels across time points. Multivariate analyses identified predictors of immune responses.

Results

The primary vaccination induced an 11‐ to 208‐fold increase in binding and neutralizing antibody levels and a 3‐ to 4‐fold increase in IFNγ/IL‐2 responses, followed by a modest decline in antibody but not cytokine responses. Booster dose induced a further 3‐ to 5‐fold increase in binding antibodies and 4‐ to 5‐fold increase in IFNγ/IL‐2, which were maintained for up to 1 year. Infections had a variable impact on immunity.

Interpretation

Humoral and cellular benefits of COVID‐19 vaccination in B‐cell‐depleted MS patients were sustained for up to 2 years when booster doses were administered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, Monoclonal, HumanizedCOVID-19 VaccinesSARS-CoV-2Multiple SclerosisHumansMaleFemaleMiddle AgedAdultLongitudinal StudiesAntibodies, ViralAntibodies, NeutralizingImmunity, CellularVaccinationImmunity, HumoralBNT162 Vaccine

Substanzen

ocrelizumabAntibodies, Monoclonal, HumanizedCOVID-19 VaccinesAntibodies, ViralAntibodies, NeutralizingBNT162 Vaccine

Autor:innen und Institutionen

  • NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
  • Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
  • Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Genentech, Inc., South San Francisco, California, USA.
  • Adaptive Biotechnologies, Seattle, Washington, USA.
  • NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Ilya Kister, Tamar E Bacon

Förderung

  • NIAID NIH HHS
  • Genentech

Zitieren

APA

Kister, I., Curtin, R., Piquet, A. L., Borko, T., Pei, J., Banbury, B. L., Bacon, T. E., Kim, A., Tuen, M., Velmurugu, Y., Nyovanie, S., Selva, S., Samanovic, M. I., Mulligan, M. J., Patskovsky, Y., Priest, J., Cabatingan, M., Winger, R. C., Krogsgaard, M., & Silverman, G. J. (2024). Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52081

Vancouver

Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, et al. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52081

BibTeX
@article{Kister2024,
  author = {Kister, Ilya and Curtin, Ryan and Piquet, Amanda L and Borko, Tyler and Pei, Jinglan and Banbury, Barbara L and Bacon, Tamar E and Kim, Angie and Tuen, Michael and Velmurugu, Yogambigai and Nyovanie, Samantha and Selva, Sean and Samanovic, Marie I and Mulligan, Mark J and Patskovsky, Yury and Priest, Jessica and Cabatingan, Mark and Winger, Ryan C and Krogsgaard, Michelle and Silverman, Gregg J},
  title = {Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52081}
}
Kostenlos starten →